Thanks to advances in treatment options, a COVID-19 diagnosis is no longer as scary as it once was, at least for most people.
Startup Celsius cuts 75% of staff ahead of first trial start for IBD drug
Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO